𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Retreatment of chronic hepatitis B e antigen–positive patients with recombinant interferon alfa-2a

✍ Scribed by Vicente Carreño; Patrick Marcellin; Stephanos Hadziyannis; Javier Salmerón; Moisés Diago; Geoge E. Kitis; Irene Vafiadis; Solko W. Schalm; Friederike Zahm; Félix Manzarbeitia; F. Javier Jiménez; Juan Antonio Quiroga

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
141 KB
Volume
30
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatitis B e antigen as a predictor for
Hepatitis B e antigen as a predictor for hepatitis B e antigen–positive chronic hepatitis B patients with peginterferon alfa-2a therapy
✍ En-Qiang Chen; Hong Tang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB 👁 1 views

PROVE1 trial, 1 in which in the group with an identical treatment schedule, the percentage of patients obtaining SVR with respect to RVR was 75% only. In other words, RVR seems easier to obtain with telaprevir, but less frequently predicts a favorable treatment outcome. A possible explanation might

Long-term outcome of hepatitis B e antig
Long-term outcome of hepatitis B e antigen–positive patients with compensated cirrhosis treated with interferon alfa
✍ G Fattovich; G Giustina; G Realdi; R Corrocher; S W Schalm 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 1 views

The aim of this study was to evaluate whether interferon alfa (IFN-alpha) treatment-associated virological and biochemical remission improves survival in a cohort of 90 white patients with compensated cirrhosis caused by hepatitis B (Child A) followed for a mean period of 7 years. Inclusion criteria

Characterization of viral kinetics in pa
Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B
✍ I-Chin Wu; Nan-Haw Chow; Pin-Nan Cheng; Wen-Chun Liu; Kung-Chia Young; Wei-Lun C 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract A study was conducted during a 1 year follow‐up to characterize the viral kinetics in hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B and to develop a model of predicting the probability of spontaneous HBeAg seroconversion. Fifty‐seven patients with HBeAg‐positive chronic hep

A randomized controlled trial of thymosi
A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody—and hepatitis B virus DNA—positive chronic hepatitis B
✍ P Andreone; C Cursaro; A Gramenzi; C Zavaglia; I Rezakovic; E Altomare; R Severi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

ment for anti-HBe-positive chronic hepatitis. The benefit It has recently been shown that thymosin-a 1 (T-a 1 ), a of this agent in producing long-term inhibition of HBV synthetic polypeptide of thymic origin, is able to proreplication must be confirmed by future trials. (HEPAmote disease remission